Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies - PubMed (original) (raw)

Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies

E Rudd et al. J Med Genet. 2006 Apr.

Abstract

Objective: To determine the frequency and spectrum of mutations in the gene encoding syntaxin 11 (STX11) in familial haemophagocytic lymphohistiocytosis (FHL), a rare autosomal recessive disorder of immune dysregulation characterised by a defect in natural killer cell function.

Methods: Mutational analysis of STX11 by direct sequencing was done in 28 FHL families that did not harbour perforin mutations, previously identified in some FHL patients. A detailed investigation of clinical features of these patients was also undertaken.

Results: Two different STX11 mutations were identified, one nonsense mutation and one deletion, affecting six of 34 children in four of 28 unrelated PRF1 negative families. Both mutations have been reported before. Three patients experienced long periods (> or = 1 year) in remission without specific treatment, which is very uncommon in this disease. Despite the milder phenotype, some children with STX11 mutations developed severe psychomotor retardation. Two of the six patients harbouring STX11 gene defects developed myelodysplastic syndrome (MDS) or acute myelogenous leukaemia (AML).

Conclusions: STX11 gene mutations were found in 14% of the PRF1 negative FHL families included in the present cohort. These results suggest that STX11 gene mutations may be associated with secondary malignancies (MDS/AML), and that there is segregation of specific clinical features in FHL patients with an underlying genotype.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: none declared.

Figures

None

Similar articles

Cited by

References

    1. Henter J ‐ I, Arico M, Elinder G, Imashuku S, Janka G. Familial hemophagocytic lymphohistiocytosis. Primary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am 199812417–433. - PubMed
    1. Katano H, Cohen J I. Perforin and lymphohistiocytic proliferative disorders. Br J Haematol 2005128739–750. - PubMed
    1. Janka G E. Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr 1983140221–230. - PubMed
    1. Henter J‐I, Samuelsson‐Horne A, Arico M, Egeler R M, Elinder G, Filipovich A H, Gadner H, Imashuku S, Komp D, Ladisch S, Webb D, Janka G. Treatment of hemophagocytic lymphohistiocytosis with HLH‐94 immunochemotherapy and bone marrow transplantation. Blood 20021002367–2373. - PubMed
    1. Stepp S E, Dufourcq‐Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew P A, Henter J I, Bennett M, Fischer A, de Saint Basile G, Kumar V. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 19992861957–1959. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources